Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
